Vycor Medical, Inc. (VYCO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 1 | 1 | 2 | 2 | 2 | - |
| Operating profit | $m | 0 | 0 | ||||||
| Net profit | $m | -1 | -1 | -0 | -0 | -0 | -0 | -0 | - |
| EPS reported | $ | -0.01 | -0.00 | ||||||
| Operating cashflow per share | $ | -0.00 | 0.00 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.00 | 0.00 | ||||||
| Free cash flow | $m | -0 | 0 | ||||||
| Net debt | $m | 1 | 1 | ||||||
| Book value equity | $m | -4 | -4 | ||||||
| Book value per share | $ | -0.12 | -0.13 | ||||||
| Number of shares | m | 33.37 | 33.37 | ||||||
| DPS (TTM paid) | $ | 0.01 | 0.01 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.99 | -0.95 | ||||||
| P/S LTM | x | 2.17 | 2.23 | ||||||
| P/FCF LTM | x | -216.00 | 67.55 | ||||||
| EV/EBITDA LTM | x | 51.38 | 52.24 | ||||||
| EV/Sales LTM | x | 2.66 | 1.65 | ||||||
| Earnings Yield LTM | % | -1.79% | -0.60% | ||||||
| FCF Yield | % | -0.46% | +1.48% | ||||||
| Quality | |||||||||
| ROE | % | +1.77% | +0.34% | ||||||
| ROIC | % | -1.10% | -2.85% | ||||||
| Operating margin | % | +1.82% | +4.91% | ||||||
| Gross margin | % | +80.58% | +82.93% | ||||||
| FCF/Sales | % | -1.00% | +5.71% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +17.24% | +13.73% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | +6.91% | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +8.03% | 0.00% | ||||||
| Dividend Growth | % | -1.46% | -1.46% | ||||||
| Payout Ratio | % | -81.68% | -2337.2% | ||||||
| FCF/Debt | x | -0.02 | 0.06 | ||||||
| Net Debt/EBITDA | x | 9.54 | 5.77 | ||||||
| EBIT/Net interest | x | 0.33 | 0.89 | ||||||
| Net debt/market cap | % | +23.68% | +40.88% | ||||||
| Net debt/Equity | x | -0.21 | -0.18 | ||||||
| Gross debt/equity | x | -0.25 | -0.23 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Vycor Medical, Inc. (VMI) is dedicated to the creation, development, and commercialization of neurological medical devices and therapeutic solutions, operating in both the United States and European markets. The company's operations are divided into two primary business units. The Vycor Medical division specializes in neurosurgical instrumentation, providing devices such as the ViewSite Brain Access System—a critical retraction and access tool used in brain and spine surgeries. Conversely, the NovaVision segment delivers advanced, non-invasive, computer-based rehabilitation programs aimed at helping individuals with vision impairments resulting from strokes or other brain injuries. VMI has also established a strategic license and transition agreement with HelferApp GmbH, authorizing HelferApp to distribute NovaVision's products and therapies to patients and healthcare providers in Austria and Switzerland. The company's main clientele consists of hospitals and various medical professionals. Established in 2005, Vycor Medical, Inc. is headquartered in Boca Raton, Florida, and functions as a subsidiary of Fountainhead Capital Management Limited.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Vycor Medical, Inc. (VMI) is dedicated to the creation, development, and commercialization of neurological medical devices and therapeutic solutions, operating in both the United States and European markets. The company's operations are divided into two primary business units. The Vycor Medical division specializes in neurosurgical instrumentation, providing devices such as the ViewSite Brain Access System—a critical retraction and access tool used in brain and spine surgeries. Conversely, the NovaVision segment delivers advanced, non-invasive, computer-based rehabilitation programs aimed at helping individuals with vision impairments resulting from strokes or other brain injuries. VMI has also established a strategic license and transition agreement with HelferApp GmbH, authorizing HelferApp to distribute NovaVision's products and therapies to patients and healthcare providers in Austria and Switzerland. The company's main clientele consists of hospitals and various medical professionals. Established in 2005, Vycor Medical, Inc. is headquartered in Boca Raton, Florida, and functions as a subsidiary of Fountainhead Capital Management Limited.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free